Sunday, June 1, 2025
Your Health 247
Advertisement
  • Home
  • Health
  • Fitness
  • Diseases
  • Nutrition
  • Weight Loss
  • Meditation
  • Wellbeing Tips
  • Suppliments
  • Yoga
No Result
View All Result
  • Home
  • Health
  • Fitness
  • Diseases
  • Nutrition
  • Weight Loss
  • Meditation
  • Wellbeing Tips
  • Suppliments
  • Yoga
No Result
View All Result
Your Health 247
No Result
View All Result
Home Diseases

Microdosing LSD for ADHD is no better than a placebo, clinical trial shows

Your Health 247 by Your Health 247
March 21, 2025
in Diseases
0 0
0
Microdosing LSD for ADHD is no better than a placebo, clinical trial shows
0
SHARES
31
VIEWS
Share on FacebookShare on Twitter


Taking low doses of LSD is not an effective treatment for ADHD. Credit: Wikimedia Commons (scientificanimations.com), CC BY-SA 4.0

Microdosing, or low-dose treatment of psychedelics such as lysergic acid diethylamide (LSD), has gained popularity in recent years as a potential method for alleviating symptoms of attention-deficit/hyperactivity disorder (ADHD). However, the first-ever randomized clinical trial investigating the pharmacological effects of psychedelics found that microdosing LSD is as effective as a placebo in improving ADHD symptoms.

Several studieshave suggested that taking repeated small doses of psychedelic substances like LSD and psilocybin—one-tenth to one-twentieth of a recreational dose that doesn’t hinder daily activities—might be beneficial for ADHD symptom management, along with improvements in well-being, cognitive function, and emotional processing.

However, most of these studies were observational and relied on self-reported data, with a significant lack of clinical evidence from controlled trials in patients.

In a study published in JAMA Psychiatry, a team of scientists from Switzerland and the Netherlands set out to evaluate the safety and effectiveness of repeated low doses of LSD in reducing ADHD symptoms in adults.

They conducted a six-week, multicenter, randomized clinical trial with 53 adults aged 18 to 65 who had been diagnosed with ADHD. Participants were randomly assigned to receive either a 20 μg dose of LSD or a placebo twice weekly to assess its impact on symptom reduction.

The study was placebo-controlled and double-blind, meaning one group received a placebo for comparison, and neither the participants nor the researchers knew who was receiving LSD and who was given the placebo.

Microdosing LSD for ADHD is no better than a placebo
A low, regular dose of LSD was physically safe and psychologically well tolerated by participants. Credit: JAMA Psychiatry (2025). DOI: 10.1001/jamapsychiatry.2025.0044

The researchers found that it was safe to administer a low dose of LSD in an outpatient setting as it is psychologically well tolerated with no recorded severe adverse effects.

The study assessed ADHD symptom severity in participants using both self-rated and observer-rated scales. Baseline assessments were conducted before treatment and the follow-up assessments after six weeks.

On a 54-point scale, where higher scores indicated more severe symptoms, the researchers observed that both LSD and placebo groups reported symptom improvement. The average scores decreased by 7 points in the LSD group and nearly 9 points in the placebo group, a difference not statistically significant to claim superiority of one treatment method over the other.

Twice-weekly microdoses of LSD were no more effective than a placebo in treating ADHD symptoms. However, the researchers suggest that alternative strategies, such as daily dosing, alternate-day dosing, or titration dosing—gradually increasing the dose in small amounts to find the optimal level without causing side effects—could potentially yield different results.

These findings challenge anecdotal claims and emphasize the necessity of placebo-controlled studies to accurately assess the impact of low-dose psychedelics on psychiatric disorders.

More information:
Lorenz Mueller et al, Safety and Efficacy of Repeated Low-Dose LSD for ADHD Treatment in Adults, JAMA Psychiatry (2025). DOI: 10.1001/jamapsychiatry.2025.0044

© 2025 Science X Network

Citation:
Microdosing LSD for ADHD is no better than a placebo, clinical trial shows (2025, March 21)
retrieved 21 March 2025
from https://medicalxpress.com/news/2025-03-microdosing-lsd-adhd-placebo-clinical.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.



Source link

Tags: ADHDclinicalLSDMicrodosingplaceboshowstrial
Previous Post

The Juicy Truth About Juice Cleanses

Next Post

With approval, Alnylam enters the ATTR-CM drug race

Next Post
With approval, Alnylam enters the ATTR-CM drug race

With approval, Alnylam enters the ATTR-CM drug race

Facebook Twitter Instagram Youtube RSS
Your Health 247

Discover the latest in health and fitness with Your Health 247. Get expert advice, workout routines, healthy recipes, and mental wellness tips to lead a healthier, happier life. Stay informed and empowered with us!

CATEGORIES

  • Diseases
  • Fitness
  • Health
  • Meditation
  • Nutrition
  • Suppliments
  • Weight Loss
  • Wellbeing Tips
  • Yoga
No Result
View All Result

SITEMAP

  • About Us
  • Advertise with Us
  • Disclaimer
  • Privacy Policy
  • DMCA
  • Cookie Privacy Policy
  • Terms and Conditions
  • Contact us

Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.

No Result
View All Result
  • Home
  • Health
  • Fitness
  • Diseases
  • Nutrition
  • Weight Loss
  • Meditation
  • Wellbeing Tips
  • Suppliments
  • Yoga

Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In